CRVS
Corvus Pharmaceuticals, Inc.
Next earnings Aug 5, 2026 · consensus $-0.16 EPS
Last earnings -5.6% on 2026-05-07
$13.05
▲ +0.77%$13.05▲ +232.06%
over 1Y
L $3.73EODHDH $25.52
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W+9.6%
1M+1.7%
3M-7.2%
YTD+78.3%
1Y+232.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Clinical-stage biotech with zero revenue, $4.6M cash against $33M R&D burn — a near-certain dilution event before any Phase 3 readout.
Corvus is a pre-revenue clinical-stage biopharma whose entire equity story rests on soquelitinib, an ITK inhibitor now in a registrational Phase 3 for relapsed T-cell lymphomas and a Phase 2 in atopic dermatitis. The 2025 numbers look superficially better — net loss narrowed to $15.3M from $62.3M — but management itself flags that the swing was driven by a $27.1M non-cash gain on warrant revaluation, not operating progress. Strip that out and the picture is uglier: operating loss widened 56% to $43.0M as R&D jumped 74% to $33.7M (soquelitinib program alone +$12.4M), and operating cash burn worsened to $32.8M.
Sources: SEC EDGAR (CIK 0001626971, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 2:10:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.